Company News »

IMS Health Announces Closing of Secondary Public Offering and Repurchase of Common Stock

Business Wire
Share on StockTwits
Published on

IMS Health Holdings, Inc. (“IMS Health”) (NYSE:IMS) today announced the closing of its secondary public offering of approximately 58 million shares of its common stock by existing shareholders affiliated with TPG Global, LLC, Canada Pension Plan Investment Board and Leonard Green & Partners, L.P., at a price to the public of $27.50 per share. The offering included 6.87 million shares sold in connection with the full exercise of the option to purchase additional shares granted to the underwriters. Of the approximately 58 million shares sold in the offering, about 11.1 million shares were repurchased by IMS Health at a price per share of $27.0875, which is equal to the midpoint between the public offering price and the price to the selling shareholders in the offering. IMS Health did not offer any stock in this transaction and did not receive any proceeds from the sale of the shares by the selling shareholders.

Goldman, Sachs & Co., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC served as joint book-running managers and as representatives of the underwriters for the offering. In addition, BofA Merrill Lynch, Wells Fargo Securities, Barclays, Deutsche Bank Securities and HSBC were joint book-running managers for the offering and TPG Capital BD, LLC, SunTrust Robinson Humphrey, Mizuho Securities, RBC Capital Markets, LLC, Piper Jaffray, William Blair & Company, L.L.C., Leerink Partners, Stifel, Fifth Third Bank and Topeka Capital Markets acted as co-managers for the offering.

An automatic shelf registration statement (including a prospectus) relating to the offering of our common stock was filed with the Securities and Exchange Commission (SEC) on May 4, 2015 and became effective upon filing. A copy of the prospectus supplement relating to the offering was filed with the SEC on May 8, 2015. You may obtain these documents free of charge by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the final prospectus supplement and the accompanying prospectus may also be obtained from: Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, facsimile at (212) 902-9316, or e-mail at prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About IMS Health

IMS Health is a leading global information and technology services company providing clients in the healthcare industry with comprehensive solutions to measure and improve their performance. End-to-end proprietary applications and configurable solutions connect 10+ petabytes of complex healthcare data through the IMS OneTM cloud platform, providing comprehensive insights into diseases, treatments, costs and outcomes. The company’s 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.

As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes.

IMSFIN

Share on StockTwits